GST : 09AUVPG8371K1ZQ
Add Review
Pragati Healthcare is an Indian FDA (CDSCO) and DGFT (Directorate General of Foreign Trade) approved pharmaceutical exporter of wide range of specialty medical products. We are an ISO 9001:2015 certified organisation, registered with Ministry of.. Read More
Head Business Development
Nihit Goyal
Year of Establishment
2012
Primary Business
Retailer
Market Covered
UK, East Europe, Australia, Middle East, CIS, South East
Natdac or Daclatasvir (brand name Daklinza) is a new medication used to treat hepatitis C. It was approved in Europe in January 2014 for treatment of adults with all genotypes of chronic hepatitis C. For some people, sofosbuvir will be the first interferon-free hepatitis C treatment option. For others, sofosbuvir can greatly shorten treatment when added to pegylated interferon and ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant. Contact us - exports@pragatihc.com
Natco Hepcinat LP (Ledipasvir + Sofosbuvir) - Harvoni is a new medication used to treat hepatitis C. It is a combination pill containing sofosbuvir (sold separately as Sovaldi) plus ledipasvir. It was approved in Europe in November 2014 for treatment of adults with genotype 1 or 4 chronic hepatitis C, and for some people with genotype 3. For many people with these genotypes, Harvoni is an interferon-free and ribavirin-free hepatitis C treatment option. Some people with harder-to-treat disease may do better if they add ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant.
Sofosbuvir (brand name Sovaldi) is a new medication used to treat hepatitis C. It was approved in Europe in January 2014 for treatment of adults with all genotypes of chronic hepatitis C. For some people, sofosbuvir will be the first interferon-free hepatitis C treatment option. For others, sofosbuvir can greatly shorten treatment when added to pegylated interferon and ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant.
Velpanat (sofosbuvir + velpatasvir) - epclusa is a new medication used to treat hepatitis c. It is a combination pill containing sofosbuvir (sold separately as sovaldi) plus velpatasvir. It was approved in europe in july 2016 for treatment of adults with all genotypes (1, 2, 3, 4, 5 and 6) of chronic hepatitis c. Epclusa is the first pangenotypic interferon-free hepatitis c treatment regimen, meaning it works against all hepatitis c genotypes. It is more effective than the older harvoni combination (sofosbuvir + ledipasvir) for people with genotype 3. Some people with harder-to-treat disease may do better if they take epclusa with ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis c such as liver cancer or needing a liver transplant.
Share your thoughts with other customers for Pragati Healthcare
Add Review
